TW202042815A - 使用布魯頓(bruton)酪胺酸激酶抑制劑治療類風性關節炎、慢性自發性蕁麻疹及全身性紅斑性狼瘡的方法 - Google Patents

使用布魯頓(bruton)酪胺酸激酶抑制劑治療類風性關節炎、慢性自發性蕁麻疹及全身性紅斑性狼瘡的方法 Download PDF

Info

Publication number
TW202042815A
TW202042815A TW109102194A TW109102194A TW202042815A TW 202042815 A TW202042815 A TW 202042815A TW 109102194 A TW109102194 A TW 109102194A TW 109102194 A TW109102194 A TW 109102194A TW 202042815 A TW202042815 A TW 202042815A
Authority
TW
Taiwan
Prior art keywords
treatment
patient
finatinib
dose
weeks
Prior art date
Application number
TW109102194A
Other languages
English (en)
Chinese (zh)
Inventor
多美子 勝本
萊斯里 琴
阿里沙 森本
大衛 詹姆斯 哈登
Original Assignee
美商建南德克公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商建南德克公司 filed Critical 美商建南德克公司
Publication of TW202042815A publication Critical patent/TW202042815A/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
TW109102194A 2019-01-22 2020-01-21 使用布魯頓(bruton)酪胺酸激酶抑制劑治療類風性關節炎、慢性自發性蕁麻疹及全身性紅斑性狼瘡的方法 TW202042815A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962795477P 2019-01-22 2019-01-22
US62/795,477 2019-01-22
US201962913270P 2019-10-10 2019-10-10
US62/913,270 2019-10-10

Publications (1)

Publication Number Publication Date
TW202042815A true TW202042815A (zh) 2020-12-01

Family

ID=69726724

Family Applications (1)

Application Number Title Priority Date Filing Date
TW109102194A TW202042815A (zh) 2019-01-22 2020-01-21 使用布魯頓(bruton)酪胺酸激酶抑制劑治療類風性關節炎、慢性自發性蕁麻疹及全身性紅斑性狼瘡的方法

Country Status (11)

Country Link
US (1) US12544372B2 (cg-RX-API-DMAC7.html)
EP (1) EP3914250A1 (cg-RX-API-DMAC7.html)
JP (3) JP2022523018A (cg-RX-API-DMAC7.html)
KR (1) KR20210119457A (cg-RX-API-DMAC7.html)
CN (3) CN113423401A (cg-RX-API-DMAC7.html)
AU (2) AU2020213265B2 (cg-RX-API-DMAC7.html)
CA (1) CA3125236A1 (cg-RX-API-DMAC7.html)
IL (1) IL284779A (cg-RX-API-DMAC7.html)
MX (2) MX2021008696A (cg-RX-API-DMAC7.html)
TW (1) TW202042815A (cg-RX-API-DMAC7.html)
WO (1) WO2020154252A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI907406B (zh) 2020-04-03 2025-12-11 美商建南德克公司 使用布魯頓氏酪胺酸激酶抑制劑來治療復發型多發性硬化症之方法
WO2024235166A1 (zh) * 2023-05-12 2024-11-21 武汉人福创新药物研发中心有限公司 含有btk抑制剂的组合物及其用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011325134B2 (en) * 2010-11-05 2014-10-23 Novartis Ag Methods of treating rheumatoid arthritis using IL-17 antagonists
UA111756C2 (uk) 2011-11-03 2016-06-10 Ф. Хоффманн-Ля Рош Аг Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона
PL4049660T3 (pl) 2016-02-29 2025-06-09 F. Hoffmann-La Roche Ag Kompozycje postaci dawkowania zawierające inhibitor kinazy tyrozynowej Brutona
WO2018175863A1 (en) 2017-03-24 2018-09-27 Genentech, Inc. Methods of treating autoimmune and inflammatory diseases

Also Published As

Publication number Publication date
CN113423401A (zh) 2021-09-21
AU2025201888A1 (en) 2025-04-03
EP3914250A1 (en) 2021-12-01
JP2026041743A (ja) 2026-03-10
AU2020213265B2 (en) 2025-01-16
CN118453606A (zh) 2024-08-09
JP2024099575A (ja) 2024-07-25
KR20210119457A (ko) 2021-10-05
CA3125236A1 (en) 2020-07-30
CN118662512A (zh) 2024-09-20
MX2025013950A (es) 2026-03-02
WO2020154252A1 (en) 2020-07-30
AU2020213265A1 (en) 2021-07-22
JP2022523018A (ja) 2022-04-21
IL284779A (en) 2021-08-31
MX2021008696A (es) 2021-08-19
US20220047588A1 (en) 2022-02-17
US12544372B2 (en) 2026-02-10

Similar Documents

Publication Publication Date Title
Daien et al. Predictive factors of response to biological disease modifying antirheumatic drugs: towards personalized medicine
JP2026041743A (ja) ブルトン型チロシンキナーゼの阻害剤を使用する関節リウマチ、慢性自発性蕁麻疹、および全身性エリテマトーデスの処置方法
Holdgate et al. Recent advances in primary Sjogren's syndrome
Dispenza et al. Diagnosis and novel approaches to the treatment of hypereosinophilic syndromes
Jung et al. Elevated salivary alpha-amylase level, association between depression and disease activity, and stress as a predictor of disease flare in systemic lupus erythematosus: A prospective case–control study
Sant’Antonio et al. A journey through infectious risk associated with ruxolitinib
JP2024119889A (ja) I型インターフェロンシグネチャー及び使用方法
Chen et al. Germinal center kinase-like kinase (GLK/MAP4K3) expression is increased in adult-onset Still's disease and may act as an activity marker
Rivera et al. Managing the risk of infection in chronic lymphocytic leukemia in the era of new therapies
Baek et al. Efficacy and safety of tocilizumab in Korean patients with active rheumatoid arthritis
Chen et al. Case report: JAKi and TNFi dual therapy is a potential treatment strategy for difficult-to-treat rheumatoid arthritis
Sriaroon et al. Biological modulators in eosinophilic diseases
US20230091561A1 (en) Methods of treating primary progressive multiple sclerosis using an inhibitor of bruton's tyrosine kinase
Leath et al. Novel and emerging therapies for asthma
HK40056367A (en) Methods of treating rheumatoid arthritis, chronic spontaneous urticaria, and systemic lupus erythematosis using an inhibitor of bruton’s tyrosine kinase
US20240368294A1 (en) Cd40l-specific tn3-derived scaffolds for use in the treatment and prevention of rheumatoid arthritis
JP2022523018A5 (cg-RX-API-DMAC7.html)
Broussais et al. Chronic myeloid leukaemia and tuberculosis in a patient with rheumatoid arthritis treated with infliximab
TADA et al. New Therapy in Rheumatoid Arthritis Biological DMARDs and JAK Inhibitors
Dona et al. Leflunomide Confers Rapid Recovery from COVID-19 and is Coupled with Temporal Immunologic Changes
Turnbulla Advanced therapies in rheumatoid
Ibrahim et al. Advances in Treatment of Juvenile Idiopathic Arthritis
TW202404595A (zh) 治療全身性紅斑性狼瘡之方法
Richards et al. Anti-Rheumatic Therapy and Comorbidity
CN118076369A (zh) Cd40l特异性tn3衍生支架及其用于治疗和预防类风湿性关节炎的方法